Trenton, NJ - Put your scientists into a classroom geared towards leadership training. This fast-paced program turns science-minded managers into capable business leaders so they can fully leverage your company's human capital. From The Laboratory To Leadership was developed exclusively for managers who are involved in the research, development and commercialization of life sciences and medical device technologies.
Trenton, NJ - On the heels of the state’s commanding presence at BIO International 2015, New Jersey’s dominance in biotechnology was validated with a top ranking nationally in the Biotech Growth Potential category in Business Facilities Magazine’s Annual Rankings Report released today.
Washington D.C. - Opposition to H.R. 9, the Innovation Act, has successfully removed the patent reform legislation from the House's pre-recess schedule. The collective voice of the life sciences community, including BioNJ and BIO, was raised in overwhelming opposition to the current version of the bill, which does not provide adequate reform to the IPR system of patent challenges at the U.S. Patent & Trademark Office (PTO).
Trenton, NJ - Dr. Stephen Ostroff, Acting Commissioner of the Food and Drug Administration (FDA), will serve as the featured luncheon speaker at the 3rd Annual BioNJ CEO Summit, Take It to the Top, scheduled for October 9 at the Bridgewater Marriott. Dr. Ostroff will participate in a fireside chat with Dr. William Hait, Global Head of Research and Development for Janssen, the pharmaceutical companies of Johnson & Johnson, entitled: Expediting Therapies and Cures to the Patients Who Need Them: The Evolving Role of the FDA.
Trenton, NJ - According to NJ Business magazine, "On June 30, the NJ Economic Development Authority (EDA) announced it is accepting applications for a second group of Executives-in-Residence at the Commercialization Center for Innovative Technologies (CCIT). The program, a joint effort organized by the EDA and BioNJ, links emerging biotechnology companies with experienced mentors to help take their businesses to the next level. Applications are open to New Jersey executives with experience in business development, health economics, regulation and other areas. More information can be found here.
Trenton, NJ - According to BioNJ, "BioNJ President and CEO Debbie Hart, along with five other New Jersey executives, including Bob Hugin, Chairman and CEO, Celgene; Sol Barer, Ph.D., Founder, Celgene, and Managing Partner, SJ Barer Consulting; Robert Hariri, M.D., Ph.D., Chairman and Founder, Celgene Cellular Therapeutics; Paul Stoffels, M.D., CSO, Johnson & Johnson; and Shirley Tilghman, Ph.D., Professor, Molecular Biology, Princeton University, were named to the Worldview 100 as six of the 100 most influential people in biotechnology."
Trenton, NJ - Continuing its commitment to providing resources to emerging New Jersey’s life sciences companies, the New Jersey Economic Development Authority (EDA) has launched its inaugural group of Executives-in-Residence. These highly-qualified life sciences executives mentor and advise emerging technology companies at the Commercialization Center for Innovative Technologies (CCIT), the EDA’s life sciences incubator. The Executive-in-Residence program was created in collaboration with BioNJ.
Philadelphia, PA - Innovation in New Jersey dates back to Einstein and Edison, but a new wave of discovery in life sciences is happening right now across the Garden State. At both the corporate and academic level, researchers throughout the state are tackling some of the industry’s biggest challenges. To showcase the state’s groundbreaking research, Choose New Jersey is launching a new concept at the New Jersey Pavilion this year: the BIO Innovation Theater.
Here is the complete schedule: http://bit.ly/1Qzf5oX
Trenton, NJ - New Jersey will showcase its business strengths in the life science industry to a global audience next week at the world’s largest biotechnology conference, BIO International, being held at the Philadelphia Convention Center on June 15-18.
Trenton, NJ - According to Debbie Hart of BioNJ, "The biotechnology industry in New Jersey continues to make significant strides and remains at the forefront of innovation. As reported in BioNJ’s industry study “Life Sciences in New Jersey,” in September 2014, there were 379 biotechnology companies operating in the state, up from 340 in 2012, representing an increase of 12 percent. New Jersey is presently ranked as the third largest biotech cluster in the country. This growth comes from new companies starting in New Jersey, companies relocating from other states and foreign-based companies establishing their US operations here."
Trenton, NJ - From June 15 to June 18, New Jersey’s life sciences prowess will be on display at the Bio International Convention in Philadelphia, the international industry event that will feature more and more than 300 academic institutions, including major research labs, and government agencies. Including ancillary professionals such as lawyers, accountants and venture capitalists, the three-day event is expected to attract more than 16,000 attendees.
Trenton, NJ – Proposed legislation that will allow greater patient access to more affordable FDA-approved biologic medicines was passed unanimously by the New Jersey Assembly Health and Human Services Committee today. The bill, A2477, also includes provisions for physician notification when a biosimilar bill is substituted for a biologic drug.
Trenton, NJ - The New Jersey Economic Development Authority (EDA) recently unveiled its inaugural Executive-in-Residence appointees. This group of highly-skilled life sciences professionals will mentor and advise emerging companies at EDA’s Commercialization Center for Innovative Technologies (CCIT) in North Brunswick. The Executive-in-Residence program was created in collaboration with BioNJ. Over the next few weeks, NJEDATech will delve into the back-stories of the six Executives-in-Residence; next up, Dana Darst, of Pennington.
Trenton, NJ - The New Jersey Economic Development Authority (EDA) last week unveiled its inaugural Executive-in-Residence appointees. This group of highly-skilled life sciences professionals will mentor and advise emerging companies at EDA’s Commercialization Center for Innovative Technologies (CCIT) in North Brunswick. The Executive-in-Residence program was created in collaboration with BioNJ. Over the next few weeks, NJEDATech will delve into the back-stories of the six Executives-in-Residence; first up, Catherine Abbadie, PhD, of Princeton.
Trenton, NJ - Tapping into the State’s broad pool of talented life sciences professionals, the New Jersey Economic Development Authority (EDA) today announced the appointment of the inaugural group of six highly-qualified professionals to its Executive-in-Residence program. Developed in collaboration with BioNJ, these professionals will mentor and advise the emerging growth companies located at the EDA’s Commercialization Center for Innovative Technologies (CCIT) in North Brunswick.
Do not miss a single innovative moment and sign up for our newsletter!